TY - JOUR
T1 - Current and Future Potential Impact of COVID-19 on Kratom (Mitragyna speciosa Korth.) Supply and Use
AU - Singh, Darshan
AU - Brown, Paula N
AU - Cinosi, Eduardo
AU - Corazza, Ornella
AU - Henningfield, Jack E
AU - Garcia-Romeu, Albert
AU - McCurdy, Christopher R
AU - McMahon, Lance R
AU - Prozialeck, Walter C
AU - Smith, Kirsten E
AU - Swogger, Marc T
AU - Veltri, Charles
AU - Walsh, Zach
AU - Grundmann, Oliver
N1 - 2020 Singh, Brown, Cinosi, Corazza, Henningfield, Garcia-Romeu, McCurdy, McMahon, Prozialeck, Smith, Swogger, Veltri, Walsh and Grundmann. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY - https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
PY - 2020/11/26
Y1 - 2020/11/26
N2 - Kratom (Mitragyna speciosa Korth., Rubiaceae) is native to and has traditional use in Southeast Asia. The number of kratom users outside of Southeast Asia has increased significantly in recent decades with use spreading to the Unites States (US) and Europe. Because of its reputed opioid-like psychoactive effects at higher doses, kratom has been regulated in several countries and is subject to an import ban by the US Food and Drug Administration. Nonetheless, in the US it is estimated that 10-15 million people consume kratom primarily for the self-treatment of pain, psychiatric disorders, to mitigate withdrawal from or dependence on opioids, and to self-treat opioid use disorder or other substance use disorders (SUDs). Due to the global COVID-19 pandemic, a shortage in the supply of kratom products may place unexpected burdens on kratom users, potentially influencing some who use kratom for SUD self-treatment to regress to harmful drug use, hence increasing the likelihood of adverse outcomes, including overdose. Inadequate treatment, treatment barriers, and increases in the sales of adulterated kratom products on the internet or in convenience stores could exacerbate circumstances further. Although there are currently no verified indications of kratom scarcity, researchers and clinicians should be aware of and remain vigilant to this unanticipated possibility.
AB - Kratom (Mitragyna speciosa Korth., Rubiaceae) is native to and has traditional use in Southeast Asia. The number of kratom users outside of Southeast Asia has increased significantly in recent decades with use spreading to the Unites States (US) and Europe. Because of its reputed opioid-like psychoactive effects at higher doses, kratom has been regulated in several countries and is subject to an import ban by the US Food and Drug Administration. Nonetheless, in the US it is estimated that 10-15 million people consume kratom primarily for the self-treatment of pain, psychiatric disorders, to mitigate withdrawal from or dependence on opioids, and to self-treat opioid use disorder or other substance use disorders (SUDs). Due to the global COVID-19 pandemic, a shortage in the supply of kratom products may place unexpected burdens on kratom users, potentially influencing some who use kratom for SUD self-treatment to regress to harmful drug use, hence increasing the likelihood of adverse outcomes, including overdose. Inadequate treatment, treatment barriers, and increases in the sales of adulterated kratom products on the internet or in convenience stores could exacerbate circumstances further. Although there are currently no verified indications of kratom scarcity, researchers and clinicians should be aware of and remain vigilant to this unanticipated possibility.
KW - COVID-19
KW - OUD
KW - SUD
KW - kratom
KW - withdrawal
UR - http://www.scopus.com/inward/record.url?scp=85097399442&partnerID=8YFLogxK
U2 - 10.3389/fpsyt.2020.574483
DO - 10.3389/fpsyt.2020.574483
M3 - Article
C2 - 33324252
SN - 1664-0640
VL - 11
JO - Frontiers in Psychiatry
JF - Frontiers in Psychiatry
M1 - 574483
ER -